Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Karl S Peggs, Eleni Tholouli, Ronjon Chakraverty, PhD, Emmanouil Nikolousis, PhD, Adrian Bloor, PhD FRCPath, Stephen Devereux, MD PhD FRCPath, Kim H. Orchard, PhD, Charles Crawley, Anne Parker, Stephen P Robinson, PhD, Frederick Chen, MDPhD, Gordon Cook, MD, Richard E Clark, MBBS MD, Kirsty Thomson, Matthew Cobb, Katy Newton, PhD, Simon Thomas, PhD, Paul Moss, PhD

Blood (2014) 124 (21): 1109.

https://doi.org/10.1182/blood.V124.21.1109.1109

Published: 2014

Journal Articles

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Emmanouil Nikolousis, Charles F. Craddock, BM, MRCP, MRCPath, Shankaranarayana Paneesha, MD, Sudhir Tauro, Prem Mahendra, II, Mark Cook, Fiona Clark, Richard Lovell, Sridhar Chaganti, Donald Milligan, MD, MBChB, Dominique Mcmullan, Mike Griffiths, Stephen P Robinson, MD

Blood (2008) 112 (11): 4409.

https://doi.org/10.1182/blood.V112.11.4409.4409

Published: 2008

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT

Stephen P Robinson, Carmen Canals, Didier Blaise, MD, Kirsty Thomson, Robert Foa, Arturo Iriondo Atienza, Jean-Luc Harousseau, Catherine Cordonnier, MD, Gordon Cook, MD, PhD, Jean-Pierre Jouet, MD, Jean-Yves Cahn, MD, PhD, Charles Crawley, Michel Attal, MD, Marek Trneny, MD, PhD, H. Tilly, Anna Sureda, MD

Blood (2008) 112 (11): 458.

https://doi.org/10.1182/blood.V112.11.458.458

Published: 2008

Journal Articles

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

Stephen P Robinson, Anna Sureda, Carmen Canals, Sr., Jean-Paul Vernant, Noel-Jean Milpied, PhD, Jürgen Finke, Johan Maertens, Jean-Pierre Jouet, MD, Charles F. Craddock, BM, MRCP, MRCPath, Karl S Peggs, MD, Steven Le Gouill, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 457.

https://doi.org/10.1182/blood.V112.11.457.457

Published: 2008

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation.

Stephen P. Robinson, MB BS, PhD, Norbert Schmitz, MD, PhD, Goli Taghipour, Anna Sureda, MD

Blood (2004) 104 (11): 2322.

https://doi.org/10.1182/blood.V104.11.2322.2322

Published: 2004

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Is Associated with Substantial Late Transplant Related Mortality and a Poor Outcome in Patients with Chemoresistant Disease.

Stephen P. Robinson, MB, BS, PhD, Norbert Schmitz, MD, PhD, Goli Taghipour, Anna Sureda, MD

Blood (2004) 104 (11): 2260.

https://doi.org/10.1182/blood.V104.11.2260.2260

Published: 2004

Journal Articles

CMV Specific Immunotherapy: How Many Patients Will Benefit?.

Russell J. Garland, PhD, Paraskevi Diamanti, PhD, Samantha E. West, PhD, Ann Green, MSc, David Carrington, PhD, Sarah J. Groves, BSc, Kerri L. Winship, BSc, Stephen P. Robinson, MD, Anthony Oakhill, MD, Jacqueline M. Cornish, MD, Derwood H. Pamphilon, MD, David I. Marks, MD, Nicholas J. Goulden, MD, Allison G. Blair, PhD, Colin G. Steward, MD

Blood (2004) 104 (11): 2244.

https://doi.org/10.1182/blood.V104.11.2244.2244

Published: 2004

Journal Articles

Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know

David I. Marks, Anne Parker, Stephen P. Robinson

Blood (2004) 104 (1): 295–296.

https://doi.org/10.1182/blood-2004-02-0765

Published: 2004

Journal Articles

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

Stephen P. Robinson, Anthony H. Goldstone, Stephen Mackinnon, Angelo Carella, Nigel Russell, Carmen Ruiz de Elvira, Goli Taghipour, Norbert Schmitz

Blood (2002) 100 (13): 4310–4316.

https://doi.org/10.1182/blood-2001-11-0107

Published: 2002

NARROW

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation.

Reduced Intensity Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Is Associated with Substantial Late Transplant Related Mortality and a Poor Outcome in Patients with Chemoresistant Disease.

CMV Specific Immunotherapy: How Many Patients Will Benefit?.

Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only